Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380051 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL29892 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL35541 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL1452757 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL3457992 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL29341 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL15229292 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL2906298 | 1.00 | HCAR2 (0.64) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL19579380 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR | |
| SCHEMBL6465406 | 0.98 | ATM (0.63) | HCAR2ATMNAAAAPPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2219553-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | Valor Medical, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009064698-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | HCAR2 781/4885ATM 652/4885NAAA 1050/4885 |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | HCAR2 781/4885ATM 652/4885NAAA 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.